Rabbit Anti-Human Lyve-1
Slide this table
|Clone Nr.||Rabbit IgG|
|Stabilizer/Carrier||BSA (50x), 0.02% sodium azide|
|Reconstitution||Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.|
|Stability and Storage||The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.|
|Preparation||Produced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). The antibody was purified via an antigen-affinity column and then biotinylated using a standard protocol.|
|Antigen||Recombinant human sLYVE-1 (RT #S01-028)|
|Synonyms||LYVE1; HAR; XLKD1; LYVE-1; CRSBP-1|
|Description||LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.|
- Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Shin-Jeong Lee et al., Sci Rep. 2015; 5: 11019.
- Aberrant lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome. YM de Mooij et al., Prenat Diagn. 2011 Feb;31(2):159-66.
All prices plus VAT + possible delivery charges